Xiangxue Pharmaceutical (300147) — Net Asset Quality Index
Xiangxue Pharmaceutical (300147) has a Net Asset Quality Index of -3.6% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥6.65 Billion minus total liabilities of CN¥6.89 Billion yields net assets of CN¥-237.24 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check Xiangxue Pharmaceutical cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Xiangxue Pharmaceutical Net Asset Quality Index Over Time (2007–2025)
This chart shows how Xiangxue Pharmaceutical's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of June 2026, the index stands at -3.6%, representing net assets of CN¥-237.24 Million against total assets of CN¥6.65 Billion CNY. See 300147 net asset value for net asset value and shareholders' equity analysis.
Annual Net Asset Quality Index for Xiangxue Pharmaceutical (2007–2025)
The table below presents the year-by-year Net Asset Quality Index for Xiangxue Pharmaceutical from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 300147 market cap.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 0.7% | CN¥43.95 Million | CN¥6.75 Billion | CN¥6.70 Billion | ▼ -18.5 pp |
| 2024 | 19.2% | CN¥1.44 Billion | CN¥7.50 Billion | CN¥6.06 Billion | ▼ -8.7 pp |
| 2023 | 27.9% | CN¥2.31 Billion | CN¥8.28 Billion | CN¥5.97 Billion | ▼ -2.2 pp |
| 2022 | 30.1% | CN¥2.82 Billion | CN¥9.35 Billion | CN¥6.53 Billion | ▼ -2.9 pp |
| 2021 | 33.0% | CN¥3.76 Billion | CN¥11.38 Billion | CN¥7.62 Billion | ▼ -10.5 pp |
| 2020 | 43.5% | CN¥4.25 Billion | CN¥9.78 Billion | CN¥5.53 Billion | ▼ -5.1 pp |
| 2019 | 48.6% | CN¥4.11 Billion | CN¥8.46 Billion | CN¥4.35 Billion | ▲ +2.1 pp |
| 2018 | 46.5% | CN¥4.01 Billion | CN¥8.63 Billion | CN¥4.61 Billion | ▲ +5.4 pp |
| 2017 | 41.1% | CN¥3.88 Billion | CN¥9.44 Billion | CN¥5.56 Billion | ▼ -5.0 pp |
| 2016 | 46.1% | CN¥3.68 Billion | CN¥7.99 Billion | CN¥4.30 Billion | ▼ -30.1 pp |
| 2015 | 76.2% | CN¥3.55 Billion | CN¥4.65 Billion | CN¥1.11 Billion | ▲ +24.1 pp |
| 2014 | 52.1% | CN¥1.87 Billion | CN¥3.59 Billion | CN¥1.72 Billion | ▲ +2.9 pp |
| 2013 | 49.2% | CN¥1.71 Billion | CN¥3.47 Billion | CN¥1.76 Billion | ▼ -2.9 pp |
| 2012 | 52.1% | CN¥1.54 Billion | CN¥2.95 Billion | CN¥1.41 Billion | ▼ -21.8 pp |
| 2011 | 73.9% | CN¥1.42 Billion | CN¥1.92 Billion | CN¥502.16 Million | ▼ -0.4 pp |
| 2010 | 74.2% | CN¥1.37 Billion | CN¥1.85 Billion | CN¥476.01 Million | ▲ +25.9 pp |
| 2009 | 48.3% | CN¥337.62 Million | CN¥698.31 Million | CN¥360.69 Million | ▲ +12.7 pp |
| 2008 | 35.6% | CN¥196.54 Million | CN¥551.47 Million | CN¥354.94 Million | ▲ +1.0 pp |
| 2007 | 34.6% | CN¥191.45 Million | CN¥553.43 Million | CN¥361.98 Million | — |